KRAS Q61

CI-VAR-00003559Explore in graph →ClinVar 177881 CIViC 203 rs17851045

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Colorectal Adenocarcinoma2
KRAS G12 OR KRAS G13 OR KRAS Q61	(prognostic)	Prognostic	B	Supports Poor Outcome	3	submitted	EID11056 The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC	civic
KRAS G12 OR KRAS G13 OR KRAS Q61	Cetuximab + ChemotherapyCombination	Predictive	B	Does Not Support Sensitivity Response	4	submitted	EID11055 The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Colorectal Neoplasm1
KRAS Q61	Cetuximab + ChemotherapyCombination	Predictive	B	Supports Resistance	4	accepted	EID3917 This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients harboring KRAS codon 61 mutations (n=13) had a… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic

Multiple Myeloma1
KRAS Q61	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID489 In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutaions in KRAS. Those with mutations had worse overall and progression free survival than those wi… (full text at CIViC) PMID 18528420 · Chng et al., 2008 · Open in CIViC	civic